Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase

Clinical Cancer Research

Volumn 3, Issue 6, 1997, Pages 911-921

  Jackman, Ann L ^a   Kimbell, Rosemary ^a   Aherne, G Wynne ^a   Brunton, Lisa ^a   Jansen, Gerrit ^b   Stephens, Trevor C ^c   Smith, Michael N ^c   Wardleworth, J Michael ^c   Boyle, F Thomas ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; 2 DEAMINO 2 METHYL 10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; ANTINEOPLASTIC AGENT; FOLINIC ACID; METHOTREXATE; N [4 [N [(3,4 DIHYDRO 2,7 DIMETHYL 4 OXO 6 QUINAZOLINYL)METHYL] N (2 PROPYNYL)AMINO] 2 FLUOROBENZOYL]GLUTAMIC ACID; NOLATREXED; PLEVITREXED; RALTITREXED; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL DIVISION; FEMALE; HUMANS; KINETICS; LEUCOVORIN; LEUKEMIA L1210; LEUKEMIA L5178; METHOTREXATE; MICE; MICE, INBRED DBA; QUINAZOLINES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0030988738     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Jackman, A. L., and Culvert, A. H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol., 6: 871-881, 1995.
2. Jackman, A. L., Jones, T. R., and Calvert, A. H. Thymidylate synthetase inhibitors: experimental and clinical aspects. In: F. M. Muggia (ed.), Experimental and Clinical Progress in Cancer Chemotherapy, pp. 155-210. Boston: Martinus Nijhoff, 1985.
3. Jackman, A. L., and Judson, I. R. The new generation of thymidylate synthase inhibitors in clinical study. Exp. Opin. Invest. Drugs, 5: 719-736, 1996.
4. Jones, T. R., Calvert, A. H., Jackman, A. L., Brown, S. J., Jones, M., and Harrap, K. R. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur. J. Cancer, 17: 11-19, 1981.
5. Jackson, R. C., Jackman, A. L., and Calvert, A. H. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, CB3717, on human lymphoblastoid cells. Biochem. Pharmacol., 32: 3783-3790, 1983.
6. Jackman, A. L., Farrugia, D. C., Gibson, W., Kimbell, R., Harrap, K. R., Stephens, T. C. Azab, M., and Boyle, F. T. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer, 31A: 1277-1282, 1995.
7. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., Judson, I. R., and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
8. Clarke, S. J., Jackman, A. L., and Judson, I. R. The history of the development and clinical use of CB3717 and ICI D1694. Adv. Exp. Med. Biol., 339: 277-287, 1993.
9. Jackman, A. L., Boyle, F. T., and Harrap, K. R. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Invest. New Drugs, in press, 1997.
10. Jackman, A. L., Gibson, W., Brown, M., Kimbell, R., and Boyle, F. T. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv. Exp. Med. Biol., 339: 265-276, 1993.
11. Duch, D. S., Banks, S., Dev, I. K., Dickerson, S. H., Ferone, R., Heath, L. S., Humphreys, J., Knick, V., Pendergast, W., Singer, S., Smith, G. K., Waters, K., and Wilson, H. R. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res., 53: 810-818, 1993.
12. Pendergast, W., Dickerson, S. H., Johnson, J. V., Dev, I. K., Ferone, R., Duch, D. S., and Smith, G. K. Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some sulfonamidobenzoylglutamate and related derivatives. J. Med. Chem., 36: 3464-3471, 1993.
13. Webber, S. E., Bleckman, T. M., Attard, J., Deal, J. G., Kathardekar, V., Welsh, K. M., Webber, S., Janson, C. A., Matthews, D. A., Smith, W. W., et al. Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J. Med. Chem., 36: 733-746, 1993.
14. Webber, S., Bartlett, C. A., Boritzki, T. J., Hilliard, J. A., Howland, E. F., Johnston, A. L., Kosa, M., Margosiak, S. A., Morse C. A., and Shetty, B. V. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother. Pharmacol., 37: 509-517, 1996.
15. Li, W. W., Waltham, M., Tong, W., Schweitzer, B. I., and Bertino, J. R. Increased activity of γ-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate. Adv. Exp. Med. Biol., 338: 635-638, 1993.
16. Pizzorno, G., Mini, E., Coronnello, M., McGuire, J. J., Moroson, B. A., Cashmore, A. R., Dreyer, R. N., Lin, J. T., Mazzei, T., Periti, P., and Bertino, J. R. Impaired polyglutamation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res., 48: 2149-2155, 1988.
17. McCloskey, D. E., McGuire, J. J., Russell, C. A., Rowan, B. G., Bertino, J. R., Pizzorno, G., and Mini, E. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol. Chem., 266: 6181-6187, 1991.
18. Pavlovic, M., Leffert, J. J., Russello, O., Bunni, M. A., Beardsley, G. P., Priest, D. G., and Pizzorno G. Altered transport of folic acid and antifolates through the carrier-mediated reduced folate transport system in a human leukemia cell line resistant to (6R) 5,10-dideazatetrahydrofolic acid (DDATHF). Adv. Exp. Med. Biol., 338: 775-778, 1993.
19. Jackman, A. L., Kelland, L. R., Kimbell, R., Brown, M., Gibson, W., Aherne, G. W., Hardcastle, A., and Boyle, F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor. ZD1694 (Tomudex), in one mouse and three human cell lines. Br. J. Cancer, 71: 914-924, 1995.
20. Takemura, Y., Kobayashi, H., Gibson, W., Kimbell, R., Miyachi, H., and Jackman, A. L. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells. Int. J. Cancer, 66: 29-36, 1996.
21. Rhee, M. S., Wang, Y., Nair, M. G., and Galivan, J. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res., 53: 2227-2230, 1993.
22. Galivan, J., Inglese, J., McGuire, J., Nimec, Z., and Coward, J. K. γ-fluoromethotrexate: synthesis and biological activity of a potent inhibitor of dihydrofolate reductase with greatly diminished ability to form poly-γ-glutamate. Proc. Natl. Acad. Sci. USA, 82: 2598-2602, 1985.
23. McGuire, J. J., Russell, C. A., Bolanowska, W. E., Freitag, C. M., Jones, C. S., and Kalman, T. I. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the γ-carboxyl group. Cancer Res., 50: 1726-1731, 1990.
24. Abraham, A., Nair, M. G., McGuire, J. J., Galivan, J., Kisliuk, R. L., and Vishnuvajjala, B. R. Antitumour efficacy of classical non-polyglutamylatable antifolates that inhibit dihydrofolate reductase. Adv. Exp. Med. Biol., 338: 663-666, 1993.
25. Boyle, F. T., Matusiak, Z. S., Hughes, L. R., Slater, A. M., Stephens, T. C., Smith, M. N., Kimbell, R., and Jackman, A. L. Substituted-2-desamino-2-methyl-quinazolinones. A series of novel antitumour agents. Adv. Exp. Med. Biol., 338: 585-588, 1993.
26. Sanghani, P. C., Jackman, A. L., Evans, V. R., Thornton, T., Hughes, L., Calvert, A. H., and Moran, R. G. A strategy for the design of membrane-permeable folylpolyglutamate synthetase inhibitors: "bay region"-substituted 2-desamino-2-methyl-5,8-dideazafolate analogues. Mol. Pharmacol., 45: 341-351, 1994.
27. Jackman, A. L., Kimbell, R., Brown, M., Brunton, L., and Boyle, F. T. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Anti-Cancer Drug Design, 10: 555-572, 1995.
28. Stephens, T. C., Smith, M. N., Waterman, S. E., McCloskey, M. L., Jackman, A. L., and Boyle, F. T. Use of murine LS178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidine synthase inhibitors. Adv. Exp. Med. Biol., 338: 589-592, 1993.
29. Marsham, P. R., Jackman, A. L., Barker, A. J., Boyle, F. T., Pegg, S. J., Wardleworth, J. M., Kimbell, R., O'Connor, B. M., Calvert, A. H., and Hughes, L. R. Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series. J. Med. Chem., 38: 994-1004, 1995.
30. 10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem. Pharmacol., 42: 1885-1895, 1991.
31. Sirotnak, F. M., DeGraw, J. I., Moccio, D. M., Samuels, L. L., and Goutas, L. New folate analogues of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother. Pharmacol., 12: 18-25, 1984.
32. 10-propargyl-5,8-dideazafolic acid (ICI 198583). J. Med. Chem., 39: 73-85, 1995.
33. Wardleworth, J. M., Boyle, F. T., Barker, R. J., Hennequin, L. F., Pegg, S. J., Stephens, T. C., Kimbell, R., Brown, M., and Jackman, A. L. ZD9331: the design and synthesis of a novel non-polyglutamatable TS inhibitor. Ann. Oncol., 5 (Suppl. 5): 247, 1994.
34. Boyle, F. T., Wardleworth, J. M., Hennequin, L. F., Kimbell, R., Marsham, P. R., Stephens, T. C., and Jackman, A. L. ZD9331: design of a novel non-polyglutamatable quinazoline-based inhibitor of thymidylate symhase. Proc. Am. Assoc. Cancer Res., 35: 302, 1994.
35. Jackman, A. L., Kimbell, R., Brown, M., Brunton, L., Bisset, G. M. F., Bavetsias, V., Marsham, P., Hughes, L. R., and Boyle, F. T. Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation. Anti-Cancer Drug Design, 10: 573-589, 1995.
36. 10-propargyl-5,8-dideazafolic acid (ICI 198583): a novel folate-based TS inhibitor. Cancer Res., 52: 1137-1143, 1992.
37. 10-propargyl-5,8-dideazafolic acid (CB 3717): development, characterization, and cross-resistance studies. Cancer Res., 46: 2810-2815, 1986.
38. Ward, W. H. J., Kimbell, R., and Jackman, A. L. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem. Pharmacol., 43: 2029-2031, 1992.
39. 10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res., 50: 5212-5218, 1990.
40. Fry, D. W., Besserer, J. A., and Boritzki, T. J. Transport of antitumour antibiotic CI-920 into LI210 leukemia cells by the reduced-folate carrier system. Cancer Res., 44: 3366-3370, 1984.
41. Jansen, G., Schornagel, J. H., Westerhof, G. R., Rijkson, G. R., Newell, D. R., and Jackman, A. L. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors. Cancer Res., 50: 7544-7548, 1990.
42. Taylor, G. A., Jackman, A. L., Balmanno, K., Hughes, L. R., and Calvert, A. H. Estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase in whole cells. In: K. Mikanagi, K. Nifhioka, and W. N. Kelley (eds.), Purine Metabolism in Man, Vol. 6, pp. 383-388. New York: Plenum Publishing Corp., 1989.
43. Yalowich, J. C., and Kalman, T. I. Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem. Pharmacol., 34: 2319-2324.
44. Aherne, G. W., Lawrence, N., Hardcastle, A., Gibson, W., Stephens, T. C., and Jackman, A. L. A sensitive competitive ELISA for the measurement of ZD9331. Proc. Am. Assoc. Cancer Res., 35: 302, 1994.
45. Jackman, A. L., Taylor, G. A., Calvert, A. H., and Harrap, K. R. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB 3717. Biochem. Pharmacol., 33: 3269-3275, 1984.
46. Stephens, T. C., Peacock, J., and Sheldon, P. W. Influence of in vitro assay conditions on the assessment of radiobiological parameters of the MT tumour. Br. J. Radiobiol., 53: 1182-1187, 1980.
47. Dev, I. K., Dallas, W. S., Ferone, R., Hanlon, M., McKee, D. D., and Yates, B. B. Mode of binding of folate analogs to thymidylate synthase. J. Biol. Chem., 269: 1873-1882, 1994.
48. Jackman, A. L., Kimbell, R., Brunton, L., Aherne, G. W., Walton, M., and Kelland, L. Activity of ZD1694 and ZD9331 in human colon and ovarian tumour cell lines. Proc. Am. Assoc. Cancer Res., 37: 382, 1996.
49. Jansen, G., Schomagel, J. M., Wardleworth, M., Boyle, F. T., Bavetsias, V., Marriott, J., and Jackman, A. L. Glutamate side chain modified quinazoline antifolate thymidylate synthase inhibitors: transport characteristics and biological evaluation. Ann. Oncol., 7 (Suppl. 1): 90, 1996.
50. Westerhof, G. R., Schornagel, J. H., Kathmann, I., Jackman, A. L., Rosowsky, A., Forsch, R. A., Hynes, J. B., Boyle, F. T., Peters, G. J., Pinedo, H. M., and Jansen, G. Carrier and receptor-mediated transport of folate antagonists targeting folate dependent enzymes: correlates of molecular-structure and biological activity. Mol. Pharmacol., 48: 459-471, 1995.
51. Aherne, W., Hardcastle, A., Kelland, L., and Jackman, A. The Measurement of deoxynucleotide (dNTP) pools by radioimmunoassay. Adv. Exp. Med. Biol., 370: 801-804, 1995.
52. Aherne, G. W., Ward, E., Dobinson, D., Hardcastle, A., and Jackman, A. L. Pharmacokinetics of a bolus injection of ZD9331, a non-polyglutamated thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res., 37: 382, 1996.
53. Stephens, T. C., Smith, M. N., McCloskey, M. L., Waterman, S. E., Gwynne, A. J., Valcaccia, B. E., Jackman, A. L., Wardleworth, J. M., and Boyle, F. T. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor: in vivo antitumour efficacy and toxicity to normal murine tissues. Proc. Am. Assoc. Cancer Res., 35: 305, 1994.